Monoclonal Antibody DNA Testing: Strengthening Quality Control in Biopharmaceutical Manufacturing

Monoclonal antibody DNA testing has become an essential part of modern biopharmaceutical manufacturing, ensuring product safety, purity, and regulatory compliance across the development lifecycle. As monoclonal antibodies (mAbs) continue to dominate biologics production for cancer therapy, autoimmune disorders, infectious diseases, and chronic illnesses, the demand for highly sensitive residual DNA testing is increasing significantly.

Monoclonal antibodies are typically produced using host-cell systems such as Chinese hamster ovary (CHO) cells, hybridoma cells, yeast, or bacterial cultures. During the production process, trace amounts of host-cell DNA may remain in the final therapeutic product. If not properly detected and controlled, these DNA fragments can create potential safety concerns, making strict DNA testing a critical quality assurance step.

The global residual DNA testing market was valued at approximately USD 312.62 million in 2025 and is expected to witness steady growth from 2026 to 2034. This growth is primarily driven by the increasing production of biologics and vaccines, along with a stronger regulatory focus on product safety and quality across global markets. The market is projected to expand at a CAGR of 5.9% during the forecast period.

Understanding Monoclonal Antibody DNA Testing

Residual DNA testing in monoclonal antibody manufacturing involves identifying and quantifying small amounts of host-cell DNA contamination that may remain after purification. Regulatory agencies such as the FDA and EMA require manufacturers to maintain strict residual DNA limits to ensure patient safety and minimize the risk of unwanted genetic material entering the final biologic product.

This testing is performed throughout upstream and downstream processes, from cell culture and fermentation to purification and final product release. It helps manufacturers maintain consistency, product integrity, and compliance with global regulatory standards.

The biologics segment dominated the Residual DNA Testing Market in 2025, driven by rising production of monoclonal antibodies and recombinant proteins. Residual DNA testing remains essential for ensuring product purity and quality control in these advanced therapies.

Key Technologies Driving Monoclonal Antibody DNA Testing

1. PCR-Based Testing

Polymerase Chain Reaction (PCR), especially quantitative PCR (qPCR), remains the most widely used technology for monoclonal antibody DNA testing. In 2025, the PCR segment held a dominant market share of 54.95% due to its high sensitivity, speed, and strong reliability for quality control applications.

qPCR allows manufacturers to detect extremely low levels of residual host-cell DNA, making it ideal for routine batch testing, validation, and final product release. Its accuracy and regulatory acceptance make it the gold standard for mAb testing.

2. Digital PCR and Next-Generation Sequencing (NGS)

Advanced platforms such as digital PCR and Next-Generation Sequencing (NGS) are improving testing precision for complex biologics. Digital PCR offers more accurate quantification at low DNA concentrations, while NGS provides deeper sequence analysis for highly sensitive contamination detection.

These technologies are becoming increasingly valuable in high-value monoclonal antibody pipelines where ultra-low DNA thresholds are required. Polaris also highlights NGS as one of the fastest-growing technology segments due to rising demand for sensitive DNA detection.

3. Standardized Testing Kits

Kits accounted for a substantial 15.5% market share in 2025 due to rising demand for standardized and pre-packaged residual DNA testing solutions.

These kits simplify workflows, reduce manual errors, and improve reproducibility across manufacturing facilities. For monoclonal antibody producers operating at large commercial scale, standardized kits help improve compliance while reducing turnaround time.

4. Automation and AI-Based Analytics

Automation is becoming a major trend in the Residual DNA Testing Market. High-throughput testing systems and AI-driven analytics improve testing efficiency, reduce turnaround time, and support large-scale monoclonal antibody production.

AI-based systems also improve data interpretation and reduce analytical variability, especially in complex biologics pipelines. Polaris identifies digital and AI-based analytics as an important market opportunity improving testing efficiency across biopharmaceutical manufacturing.

Growth Drivers of the Residual DNA Testing Market

Several major factors are accelerating demand for monoclonal antibody DNA testing:

• Rising production of monoclonal antibodies and recombinant proteins
• Increasing oncology and autoimmune disease biologics pipelines
• Growing regulatory focus on product purity and patient safety
• Expansion of CDMOs and outsourced analytical testing
• Rising adoption of gene and cell therapies
• Strong demand for standardized quality control workflows

The report also notes that gene therapy is projected to grow at the fastest CAGR due to the increasing complexity of advanced biologics requiring highly sensitive DNA contamination analysis.

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/residual-dna-testing-market

Key Players

• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• Charles River Laboratories International Inc.
• Danaher Corporation
• Eurofins Scientific SE
• Lonza Group AG
• Merck KGaA
• PerkinElmer Inc.
• QIAGEN N.V.
• Sartorius AG
• SGS SA
• Thermo Fisher Scientific Inc.

Regional Market Insights

North America dominated the Residual DNA Testing Market in 2025 with a 43.72% revenue share, supported by strong biologics production, advanced biopharmaceutical infrastructure, and strict regulatory requirements for product safety. The U.S. accounted for nearly 80% of North America’s revenue share.

Meanwhile, Asia Pacific is projected to grow at the fastest CAGR of 6.5%, driven by rapid expansion of biologics manufacturing, rising monoclonal antibody production, and increasing investments in biotech infrastructure across India and China.

Challenges Limiting Market Expansion

Despite strong growth potential, several barriers remain:

• High cost of advanced testing technologies
• Complex validation requirements for new testing platforms
• Regulatory approval challenges across global markets
• Need for highly skilled laboratory professionals
• Infrastructure limitations for smaller manufacturers

These challenges may slow adoption, particularly among emerging biotech firms and smaller-scale biologics manufacturers.

Future Outlook

The future of monoclonal antibody DNA testing looks highly promising as biologics continue to dominate pharmaceutical innovation. With increasing focus on precision manufacturing, regulatory compliance, and patient safety, residual DNA testing is becoming a non-negotiable part of monoclonal antibody production.

The broader Residual DNA Testing Market will continue to grow as biopharmaceutical companies invest in faster, smarter, and more reliable analytical technologies. From PCR innovation to AI-powered automation, the future of biologics quality assurance will be strongly shaped by advances in monoclonal antibody DNA testing.

More Trending Latest Reports By Polaris Market Research:

Catheters Market

Neovagina Surgery Market

Human Growth Hormone Market

U.S. AAMI Level 3 Surgical Gown Market

Ebola Vaccines Market

Dermatology Device Market

U.S. Diabetes Devices Market

Anti-pollution Nasal Spray Market